Palatin Announces $10 Million Registered Direct Offering
30 Jan, 2024, 08:00 ET CRANBURY, N.J., Jan. 30, 2024 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with healthcare-focused institutional investors for […]
Palatin Announces $10 Million Registered Direct Offering Read More »